MedGenome Appoints Felix Olale as CEO
Felix Olale, M.D., Ph.D., President and Chief Executive Officer, MedGenome U.S. ● Photo Credit: MedGenome
FOSTER CITY, Calif., October 26, 2024 (VSNewsNetwork.com) – MedGenome, a biotechnology company that specializes in multiomics and precision medicine, has announced the appointment of Felix Olale, M.D., Ph.D., as President and Chief Executive Officer, and Jennifer Rose as Executive Vice President and Chief Commercial Officer. The new leadership team will oversee the company’s expansion in the U.S., focusing on driving innovation in personalized medicine and multiomics solutions.
Dr. Olale, who previously served as Global Co-Lead of Healthcare Investments at LeapFrog Investments, brings experience in genomics and healthcare to MedGenome. His role will be to advance the company’s partnerships with academic institutions and biopharma companies seeking multiomic and genomic technologies to support drug discovery and treatment of unmet medical needs.
Jennifer Rose, Executive Vice President and Chief Commercial Officer, MedGenome U.S. ● Photo Credit: MedGenome
"MedGenome is at the forefront of innovation, partnering with researchers and biopharma companies who seek more than just multiomics services—they are looking for a true collaborator to unlock deeper insights into the biology of disease. Jennifer and I are excited to lead this next phase of growth, leveraging our comprehensive multiomic platform to drive breakthroughs in personalized medicine, drug discovery, and genetic disease treatment. Our goal is to combine these advanced technologies with AI and machine learning to deliver precision medicine solutions that will reshape healthcare," said Olale.
Jennifer Rose, who previously held leadership roles at Precision for Medicine, NeoGenomics Laboratories, and GE Healthcare, will focus on expanding MedGenome’s commercial partnerships in the U.S. and globally. She brings prior experience in life sciences and business development, with a strong background in building partnerships with biopharma companies.
@VSNewsNetwork
@VSNewsNetwork
"MedGenome’s unparalleled global reach, especially in India, South Asia, Africa, and Latin America, combined with our advanced capabilities in spatial transcriptomics, single-cell sequencing, long-read technologies, and genomics-driven antibody drug discovery, uniquely positions us to deliver cutting-edge solutions for drug discovery, novel diagnostics, and personalized therapies. We are committed to partnering with biopharma to harness these transformative technologies, revolutionizing patient care and improving outcomes for millions worldwide," said Rose.
MedGenome U.S., based in Foster City, California, offers a range of multiomic services integrating genomics, epigenomics, transcriptomics, and proteomics. The company collaborates with researchers and biopharma companies to tackle complex challenges in rare diseases, oncology, and genetic disorders.
"With Felix leading our North American operations and Dr. Vedam Ramprasad driving our business in India, we have the leadership team in place to accelerate MedGenome’s growth and dramatically expand its global impact," said Mahesh Pratapneni, CEO of MedGenome.
For more information about MedGenome, visit www.medgenome.com.
Source: MedGenome
